IQWIG method paper in development

The German pharma industry association has recently circulated a briefing document around the new method paper/process of IQWIG assessment in Germany. As it looks like only after a relative effectiveness assessment has been proven better utility for the new drug - as before based on RCT's only! - a cost-benefit assessment will be conducted... (still max prices apparently will apply) modeling and QALY's should apparently not be part of the equation... the industry association protests against missing international standards.. Germany's HTA remains mysterious so far.

No comments: